ImmuCell Corporation ICCC
9.93
(0.04)
(0.40%)
as of 25 Sep
- Market cap
- $90.6M
- P/E
- 117×
Follow ICCC
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
118.79 | 0.00 | 0.00 | 23.62 |
+8 more quarters Free account |
P/S ratio |
2.97 | 1.91 | 2.01 | 2.04 | |
P/FCF ratio |
21.53 | 16.73 | 44.02 | 75.74 | |
P/Operating CF |
30.18 | 16.03 | 115.05 | (47.81) | |
P/B ratio |
2.90 | 1.97 | 2.05 | 1.90 | |
Price to Tangible BV |
2.91 | 1.97 | 2.06 | 1.90 | |
EV/Sales |
2.95 | 1.98 | 2.20 | 2.24 | |
EV/EBITDA |
14.40 | 11.53 | 13.72 | 12.21 | |
EV/Operating CF |
15.37 | 13.22 | 24.56 | 31.23 | |
EV/FCF |
21.40 | 17.28 | 48.22 | 83.24 | |
Quick Ratio |
2.65 | 2.43 | 1.82 | 1.61 | |
Current Ratio |
4.75 | 4.82 | 4.26 | 4.21 | |
Net Debt/EBITDA |
(0.23) | 0.76 | 8.12 | 7.69 | |
Debt/Assets |
17.81% | 19.73% | 21.39% | 20.75% | |
Debt/Equity |
0.26 | 0.30 | 0.34 | 0.32 | |
Asset Turnover |
0.66 | 0.67 | 0.63 | 0.62 | |
Operating CF/Net income |
1.65 | 1.84 | (0.17) | 8.46 | |
Capex/Depreciation |
(1.55) | (0.31) | (0.24) | (0.84) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1.67% | 3.07% | 9.95% | 12.61% | |
Selling, General and Administrative Expense of Revenue |
33.16% | 22.89% | 28.97% | 29.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
3.34% | 1.33% | 1.36% | 1.33% | |
Graham Net Nets |
0.06 | 0.07 | 0.03 | 0.02 | |
Graham Number |
2.57 | 0.00 | 0.00 | 4.43 | |
Earnings Yield |
0.84% | (0.88%) | (1.71%) | 4.23% | |
Free Cash Flow Yield |
4.64% | 5.98% | 2.27% | 1.32% | |
Revenue per Share |
0.79 | 1.15 | 0.84 | 0.61 | |
Operating CF per Share |
0.33 | 0.40 | 0.05 | (0.13) | |
Capex per Share |
(0.08) | (0.02) | (0.02) | (0.07) | |
Free Cash Flow per Share |
0.25 | 0.38 | 0.03 | (0.20) | |
Cash per Share |
0.98 | 0.75 | 0.42 | 0.43 | |
Shareholders Equity per Share |
3.46 | 3.22 | 3.00 | 3.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.46 | 3.22 | 3.00 | 3.29 | |
Free Cash Flow |
2.29 | 3.41 | 0.32 | (1.77) | |
Working Capital |
16.64 | 14.95 | 12.97 | 12.83 | |
Capital Expenditures |
(0.73) | (0.17) | (0.17) | (0.59) | |
Net Current Asset Value |
5.82 | 3.89 | 1.47 | 0.90 | |
EV/EBIT |
23.42 | 23.65 | 36.87 | 26.69 | |
Capex to Sales |
0.10 | 0.02 | 0.02 | 0.11 | |
Net Profit Margin |
25.53% | 18.75% | (37.36%) | (2.54%) | |
Price to Operating Income |
23.56 | 22.90 | 33.66 | 24.28 | |
| Other line items | |||||
Average Receivables |
2.64 | 3.02 | 3.60 | 2.43 | |
Average Payables |
2.70 | 2.08 | 2.38 | 2.41 | |
Average Inventory |
8.69 | 8.02 | 8.19 | 8.63 | |
Average Assets |
46.68 | 44.87 | 43.82 | 45.09 | |
Average Common Equity |
30.62 | 29.06 | 27.29 | 28.11 |
Columns are period end dates